Cholecystokinin
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
| Cholecystokinin | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||
| Symbols | CCK ; MGC117187 | ||||||||||
| External IDs | Template:OMIM5 Template:MGI HomoloGene: 583 | ||||||||||
| |||||||||||
| RNA expression pattern | |||||||||||
 | |||||||||||
| More reference expression data | |||||||||||
| Orthologs | |||||||||||
| Template:GNF Ortholog box | |||||||||||
| Species | Human | Mouse | |||||||||
| Entrez | n/a | n/a | |||||||||
| Ensembl | n/a | n/a | |||||||||
| UniProt | n/a | n/a | |||||||||
| RefSeq (mRNA) | n/a | n/a | |||||||||
| RefSeq (protein) | n/a | n/a | |||||||||
| Location (UCSC) | n/a | n/a | |||||||||
| PubMed search | n/a | n/a | |||||||||
| Cholecystokinin | |
|---|---|
 CCK identified at bottom right. | |
| Identifiers | |
| Symbol | CCK |
| Entrez | 885 |
| HUGO | 1569 |
| OMIM | 118440 |
| RefSeq | NM_000729 |
| UniProt | P06307 |
| Other data | |
| Locus | Chr. 3 pter-p21 |
|
WikiDoc Resources for Cholecystokinin |
|
Articles |
|---|
|
Most recent articles on Cholecystokinin Most cited articles on Cholecystokinin |
|
Media |
|
Powerpoint slides on Cholecystokinin |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Cholecystokinin at Clinical Trials.gov Trial results on Cholecystokinin Clinical Trials on Cholecystokinin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Cholecystokinin NICE Guidance on Cholecystokinin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Cholecystokinin Discussion groups on Cholecystokinin Patient Handouts on Cholecystokinin Directions to Hospitals Treating Cholecystokinin Risk calculators and risk factors for Cholecystokinin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Cholecystokinin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Cholecystokinin (CCK; from Greek chole, "bile"; cysto, "sac"; kinin, "move"; hence, move the bile-sac (gallbladder)) is a peptide hormone of the gastrointestinal system responsible for stimulating the digestion of fat and protein. Cholecystokinin, previously called pancreozymin, is synthesised by I-cells in the mucosal epithelium of the small intestine and secreted in the duodenum, the first segment of the small intestine, and causes the release of digestive enzymes and bile from the pancreas and gallbladder, respectively. It also acts as a hunger suppressant. Recent evidence has suggested that it also plays a major role in inducing drug tolerance to opioids like morphine and heroin, and is partly implicated in experiences of pain hypersensitivity during opioid withdrawal.[1][2]
Structure
CCK is composed of varying numbers of amino acids (e.g., CCK58, CCK33, CCK8) depending on post-translational modification of the CCK gene product, preprocholecystokinin. CCK is very similar in structure to gastrin, another of the gastrointestinal hormones, so much so that the last five C-terminal amino acids are same as those of gastrin. CCK58 comprises a helix-turn-helix configuration.
Release and Function
CCK mediates a number of physiological processes, including digestion and satiety.
Digestion
Secretion of CCK by the duodenal and intestinal mucosa is stimulated by fat- or protein-rich chyme entering the duodenum. It then inhibits gastric emptying and gastric acid secretion and mediates digestion in the duodenum. It acts on the pancreas to stimulate the secretion of a juice rich in pancreatic digestive enzymes. Together these enzymes catalyze the digestion of fat, protein, and carbohydrates. Thus the levels of the substances which stimulated the release of CCK drop and the concentration of the hormone drops as well. The release of CCK is also inhibited by somatostatin.
CCK also causes the increased production of hepatic bile, and stimulates the contraction of the gallbladder and the relaxation of the Sphincter of Oddi (Glisson's sphincter), resulting in the delivery of bile into the duodenal part of the small intestine. Bile salts form amphipathic micelles that emulsify fats, aiding in their digestion and absorption.
Neurobiology
As a neuropeptide, CCK mediates satiety by acting on the CCK receptors distributed widely throughout the central nervous system. In humans, it has been suggested that CCK administration causes nausea and anxiety, and weakly decreases the desire to eat is the reason for CCK administration to induce a satiating effect. Some studies have given a strong correlation for the satiating effect, but have not proven or disproven that CCK administration causes nauseau or anxiety Benoit et al (2003).[3] The mechanism for this hunger suppression is thought to be a decrease in the rate of gastric emptying.[4]
The effects of CCK vary between individuals. For example, in rats, CCK administration significantly reduces hunger in young males, but is slightly less effective in older subjects, and even slightly less effective in females. The hunger-suppressive effects of CCK also are reduced in obese rats.[5]
See also
References
- ↑ Kissin I, Bright CA, Bradley EL (2000). "Acute tolerance to continuously infused alfentanil: the role of cholecystokinin and N-methyl-D-aspartate-nitric oxide systems". Anesth. Analg. 91 (1): 110–6. doi:10.1097/00000539-200007000-00021. PMID 10866896.
- ↑ Fukazawa Y, Maeda T, Kiguchi N, Tohya K, Kimura M, Kishioka S (2007). "Activation of spinal cholecystokinin and neurokinin-1 receptors is associated with the attenuation of intrathecal morphine analgesia following electroacupuncture stimulation in rats". J. Pharmacol. Sci. 104 (2): 159–66. doi:10.1254/jphs.FP0070475. PMID 17558184.
- ↑ Greenough A, Cole G, Lewis J, Lockton A, Blundell J (1998). "Untangling the effects of hunger, anxiety, and nausea on energy intake during intravenous cholecystokinin octapeptide (CCK-8) infusion". Physiol. Behav. 65 (2): 303–10. doi:10.1016/S0031-9384(98)00169-3. PMID 9855480.
- ↑ Shillabeer G, Davison JS (1987). "Proglumide, a cholecystokinin antagonist, increases gastric emptying in rats". Am. J. Physiol. 252 (2 Pt 2): R353–60. PMID 3812772.
- ↑ Fink H, Rex A, Voits M, Voigt JP (1998). "Major biological actions of CCK--a critical evaluation of research findings". Exp Brain Res. 123 (1–2): 77–83. doi:10.1007/s002210050546. PMID 9835394.
External links
- Cholecystokinin at the US National Library of Medicine Medical Subject Headings (MeSH)
- Essentials of Human Physiology by Thomas M. Nosek. Section 6/6ch2/s6ch2_14.
de:Cholecystokinin it:Colecistochinina nl:Cholecystokinine sr:Холецистокинин fi:Kolekystokiniini sv:Cholecystokinin